Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Debiopharm Brings Towa before Supreme Court over Elplat
March 14, 2017
- 1st Line Use, Administration Interval Will Be Key Differentiator for Keytruda: MSD Japan Chief
March 14, 2017
- Yoshiki Ito Named as New Alexion Japan President
March 14, 2017
- Pfizer Initiates Voluntary Recall of EpiPen 0.3 mg in Japan
March 14, 2017
- UMN, Astellas Agree on Termination of Joint Flu Vaccine Programs
March 13, 2017
- Eisai CEO Has High Hopes on Combinations of Alzheimer’s Pipelines
March 10, 2017
- Takecab Most Heavily Pitched Drug in HP Market in January: Anterio
March 9, 2017
- Yutaka Shibata to Helm Asahi Kasei Pharma
March 9, 2017
- Pfizer’s FY2016 Japan Sales Slide 7.4% on Price Cuts, Generic Erosions
March 9, 2017
- Fujifilm Succeeds at Increasing Anti-Inflammatory Action of Mesenchymal Stem Cells, Expects Uses in Regenerative Medicine
March 9, 2017
- Average Drug R&D Spending in Japan Up 1.46 Billion Yen in FY2015
March 8, 2017
- Ethical Drug Sales Down 6.8% in January: Crecon
March 8, 2017
- Avelumab Filed in Japan for Merkel Cell Carcinoma: Merck Serono/Pfizer
March 8, 2017
- Taiho Forms Canadian Unit for Lonsurf Rollout
March 8, 2017
- Edoxaban Study in Post-PCI AF Patients Underway: Daiichi Sankyo
March 8, 2017
- Fujifilm, Kyowa Kirin JV Wins Humira Patent Litigation in UK
March 7, 2017
- Mochida, Fuji Yakuhin Link Arms on Hyperuricemia Candidate
March 7, 2017
- Maruho Group to See 1st Overseas Launch Next Month with Acne Med
March 7, 2017
- Kanako Kikuchi to Become Japan Chief of GSK
March 7, 2017
- Otsuka to Buy Neurovance, Gets Its Hands on Non-Stimulant ADHD Med
March 6, 2017
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…